Treatment of an Adolescent With Chronic Myeloid Leukemia and the T315I Mutation With Ponatinib

被引：21
|
作者：
Nickel, Robert Sheppard [1 ]
Daves, Marla [1 ]
Keller, Frank [1 ]
机构：
[1] Emory Univ, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA
来源：
PEDIATRIC BLOOD & CANCER | 2015年 / 62卷 / 11期
关键词：
IMATINIB; GROWTH; CHILDREN;
D O I：
10.1002/pbc.25551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2050 / 2051
页数：2
相关论文
共 50 条
  • [21] Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation
    Palukuri, N. R.
    Stalin, B.
    Chennamaneni, R.
    Prasad, S. K.
    Konatam, M. L.
    Gundeti, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation
    de Lavallade, Hugues
    Khorashad, Jamshid S.
    Davis, Howard P.
    Milojkovic, Dragana
    Kaeda, Jaspal S.
    Goldman, John M.
    Apperley, Jane F.
    Marin, David
    BLOOD, 2007, 110 (07) : 2779 - 2780
  • [23] Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment
    Minami, Yosuke
    Kajiguchi, Tomohiro
    Abe, Akihiro
    Ohno, Toshihito
    Kiyoi, Hitoshi
    Naoe, Tomoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (04) : 664 - 666
  • [24] Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation
    Goodrich, Angelina Daisy
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (05) : 513 - 515
  • [25] Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment
    Yosuke Minami
    Tomohiro Kajiguchi
    Akihiro Abe
    Toshihito Ohno
    Hitoshi Kiyoi
    Tomoki Naoe
    International Journal of Hematology, 2010, 92 : 664 - 666
  • [26] Current status of agents active against the T315I chronic myeloid leukemia phenotype
    Burke, Aine Carol
    Swords, Ronan T.
    Kelly, Kevin
    Giles, Francis J.
    EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (01) : 85 - 103
  • [27] Characteristics and outcome of patients with chronic myeloid leukemia (CML) and T315I mutation following failure of imatinib mesylate therapy
    Jabbour, Elias
    Kantarjiah, Hagop
    Jones, Dan
    Verstovsek, Srdan
    Ferrajoli, Alessandra
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 577A - 578A
  • [28] Lack of BCR-ABL T315I Mutation in Tunisian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
    El Aoud, Amina
    Kamoun, Hassen
    Frikha, Rim
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 267 - 268
  • [29] A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
    Tomassetti, Sarah
    Lee, Jennifer
    Qing, Xin
    CLINICAL CASE REPORTS, 2022, 10 (11):
  • [30] Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC
    Deininger, Michael
    Apperley, Jane
    Arthur, Christopher Kevin
    Chuah, Charles
    Hochhaus, Andreas
    de Lavallade, Hugues
    Lipton, Jeffrey Howard
    Lomaia, Elza
    McCloskey, James K.
    Maness, Lori J.
    Mauro, Michael J.
    Moiraghi, Beatriz
    Pavlovsky, Carolina
    Rosti, Gianantonio
    Rousselot, Philippe
    Sutton, Maria Undurraga
    Ren, Xiaowei
    Vorog, Alexander
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345